These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 20570632)

  • 1. H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells.
    Hadzijusufovic E; Peter B; Gleixner KV; Schuch K; Pickl WF; Thaiwong T; Yuzbasiyan-Gurkan V; Mirkina I; Willmann M; Valent P
    Exp Hematol; 2010 Oct; 38(10):896-907. PubMed ID: 20570632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro effects of histamine receptor 1 antagonists on proliferation and histamine release in canine neoplastic mast cells.
    Gamperl S; Stefanzl G; Willmann M; Valent P; Hadzijusufovic E
    Vet Med Sci; 2021 Jan; 7(1):57-68. PubMed ID: 32924324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
    Gleixner KV; Mayerhofer M; Sonneck K; Gruze A; Samorapoompichit P; Baumgartner C; Lee FY; Aichberger KJ; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P
    Haematologica; 2007 Nov; 92(11):1451-9. PubMed ID: 18024392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
    Gleixner KV; Mayerhofer M; Cerny-Reiterer S; Hörmann G; Rix U; Bennett KL; Hadzijusufovic E; Meyer RA; Pickl WF; Gotlib J; Horny HP; Reiter A; Mitterbauer-Hohendanner G; Superti-Furga G; Valent P
    Blood; 2011 Aug; 118(7):1885-98. PubMed ID: 21680801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.
    Peter B; Bibi S; Eisenwort G; Wingelhofer B; Berger D; Stefanzl G; Blatt K; Herrmann H; Hadzijusufovic E; Hoermann G; Hoffmann T; Schwaab J; Jawhar M; Willmann M; Sperr WR; Zuber J; Sotlar K; Horny HP; Moriggl R; Reiter A; Arock M; Valent P
    Leukemia; 2018 Apr; 32(4):1016-1022. PubMed ID: 29249817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).
    Peter B; Hadzijusufovic E; Blatt K; Gleixner KV; Pickl WF; Thaiwong T; Yuzbasiyan-Gurkan V; Willmann M; Valent P
    Exp Hematol; 2010 Sep; 38(9):782-91. PubMed ID: 20685234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation.
    Hadzijusufovic E; Peter B; Herrmann H; Rülicke T; Cerny-Reiterer S; Schuch K; Kenner L; Thaiwong T; Yuzbasiyan-Gurkan V; Pickl WF; Willmann M; Valent P
    Allergy; 2012 Jul; 67(7):858-68. PubMed ID: 22583069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412.
    Aichberger KJ; Mayerhofer M; Gleixner KV; Krauth MT; Gruze A; Pickl WF; Wacheck V; Selzer E; Müllauer L; Agis H; Sillaber C; Valent P
    Blood; 2007 Apr; 109(7):3031-41. PubMed ID: 17110460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V.
    Gleixner KV; Peter B; Blatt K; Suppan V; Reiter A; Radia D; Hadzijusufovic E; Valent P
    Haematologica; 2013 Sep; 98(9):1450-7. PubMed ID: 23539538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihistamine activity, central nervous system and cardiovascular profiles of histamine H1 antagonists: comparative studies with loratadine, terfenadine and sedating antihistamines in guinea-pigs.
    Hey JA; Del Prado M; Cuss FM; Egan RW; Sherwood J; Lin CC; Kreutner W
    Clin Exp Allergy; 1995 Oct; 25(10):974-84. PubMed ID: 8556569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand.
    Ghanim V; Herrmann H; Heller G; Peter B; Hadzijusufovic E; Blatt K; Schuch K; Cerny-Reiterer S; Mirkina I; Karlic H; Pickl WF; Zöchbauer-Müller S; Valent P
    Blood; 2012 May; 119(18):4242-52. PubMed ID: 22438247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.
    Aichberger KJ; Gleixner KV; Mirkina I; Cerny-Reiterer S; Peter B; Ferenc V; Kneidinger M; Baumgartner C; Mayerhofer M; Gruze A; Pickl WF; Sillaber C; Valent P
    Blood; 2009 Dec; 114(26):5342-51. PubMed ID: 19850739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Terfenadine induces anti-proliferative and apoptotic activities in human hormone-refractory prostate cancer through histamine receptor-independent Mcl-1 cleavage and Bak up-regulation.
    Wang WT; Chen YH; Hsu JL; Leu WJ; Yu CC; Chan SH; Ho YF; Hsu LC; Guh JH
    Naunyn Schmiedebergs Arch Pharmacol; 2014 Jan; 387(1):33-45. PubMed ID: 24048439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.
    Hadzijusufovic E; Peter B; Rebuzzi L; Baumgartner C; Gleixner KV; Gruze A; Thaiwong T; Pickl WF; Yuzbasiyan-Gurkan V; Willmann M; Valent P
    Vet Immunol Immunopathol; 2009 Dec; 132(2-4):243-50. PubMed ID: 19505729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells.
    Gleixner KV; Rebuzzi L; Mayerhofer M; Gruze A; Hadzijusufovic E; Sonneck K; Vales A; Kneidinger M; Samorapoompichit P; Thaiwong T; Pickl WF; Yuzbasiyan-Gurkan V; Sillaber C; Willmann M; Valent P
    Exp Hematol; 2007 Oct; 35(10):1510-21. PubMed ID: 17681669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells.
    Gamperl S; Stefanzl G; Peter B; Smiljkovic D; Bauer K; Willmann M; Valent P; Hadzijusufovic E
    Vet Comp Oncol; 2019 Dec; 17(4):553-561. PubMed ID: 31286638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells.
    Krauth MT; Mirkina I; Herrmann H; Baumgartner C; Kneidinger M; Valent P
    Clin Exp Allergy; 2009 Nov; 39(11):1711-20. PubMed ID: 19860818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.
    Peter B; Gleixner KV; Cerny-Reiterer S; Herrmann H; Winter V; Hadzijusufovic E; Ferenc V; Schuch K; Mirkina I; Horny HP; Pickl WF; Müllauer L; Willmann M; Valent P
    Haematologica; 2011 May; 96(5):672-80. PubMed ID: 21242189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis.
    Hadzijusufovic E; Rebuzzi L; Gleixner KV; Ferenc V; Peter B; Kondo R; Gruze A; Kneidinger M; Krauth MT; Mayerhofer M; Samorapoompichit P; Greish K; Iyer AK; Pickl WF; Maeda H; Willmann M; Valent P
    Exp Hematol; 2008 Nov; 36(11):1461-70. PubMed ID: 18723263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of H1-antihistamines on histamine release from dispersed canine cutaneous mast cells.
    García G; DeMora F; Ferrer L; Puigdemont A
    Am J Vet Res; 1997 Mar; 58(3):293-7. PubMed ID: 9055977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.